COHANCE - Cohance Life
📢 Recent Corporate Announcements
Cohance Lifesciences Limited has approved the grant of 1,98,711 stock options to eligible employees of the company and its subsidiaries. These options are granted under the Employee Stock Option Plan 2023 (ESOP 2023) and each option is convertible into one equity share of Re. 1 face value. The vesting period for these options ranges from a minimum of one year to a maximum of ten years. This move is a standard corporate practice aimed at employee retention and aligning workforce interests with long-term company performance.
- Grant of 1,98,711 stock options to eligible employees under ESOP 2023
- Each stock option carries the right to apply for one equity share of face value Re. 1
- Vesting period is set for a minimum of 1 year and a maximum of 10 years from the grant date
- Options can be exercised within 3 years from the date of vesting
- The scheme is compliant with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals, has scheduled a meeting with institutional investors and analysts on March 13, 2026. The management will be participating in the Investec CDMO Day held in Hyderabad. The interaction is categorized as a group meeting aimed at providing business updates. The company has explicitly stated that no unpublished price-sensitive information will be shared during this roadshow.
- Management to participate in Investec CDMO Day in Hyderabad on March 13, 2026.
- The interaction is scheduled as a group meeting with various institutional investors.
- Company confirms that no unpublished price-sensitive information (UPSI) will be disclosed.
- The meeting schedule is subject to change based on exigencies from either party.
- Disclosure follows Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals, has announced its participation in two major investor conferences in Mumbai. The management will attend the IIFL Entrepreneurial India Conference on February 25, 2026, and the Kotak Chasing Growth Conference on February 26, 2026. These meetings will be conducted in both group and one-on-one formats. The company has clarified that no unpublished price-sensitive information will be shared during these interactions.
- Scheduled to attend IIFL Entrepreneurial India Conference on February 25, 2026
- Scheduled to attend Kotak Chasing Growth Conference on February 26, 2026
- Meetings will be held in Mumbai in Group and One-on-one formats
- Company confirms no unpublished price-sensitive information (UPSI) will be disclosed
Cohance Lifesciences reported a challenging Q3 FY26, with Pharma CDMO revenue declining 27% YoY due to inventory destocking and patent expiries in key molecules. Consequently, the company has revised its FY26 revenue guidance to an early-to-mid double-digit decline, citing a transition year impacted by customer-led timing delays. Despite these headwinds, the company maintains a robust pipeline with 9 Phase 3 programs and expects a recovery in FY27 driven by new product launches. Management is also investing $10 million in US-based capacity to strengthen its Antibody-Drug Conjugate (ADC) platform.
- Revised FY26 revenue outlook downward to an early-to-mid double-digit decline.
- Pharma CDMO revenue fell 27% YoY in Q3 FY26, though adjusted growth was 7% excluding destocking.
- Currently supporting 9 Phase 3 molecules, with 4 expected to move into commercial supply in FY27.
- Investing $10 million in a cGMP US-based expansion for ADC supply capability by end of FY27.
- Nacharam facility remediation is ongoing following a USFDA warning letter, with production resumed for non-US markets.
Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals, has released the audio recording of its earnings conference call held on February 12, 2026. The call discussed the financial performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is part of the company's regulatory compliance under SEBI LODR Regulations. Investors can access the full recording via the link provided in the official filing on the company's website.
- Audio recording for Q3 and 9M FY26 earnings call is now publicly available.
- The conference call was conducted on February 12, 2026, following the results announcement.
- Disclosure made in compliance with SEBI Regulation 30 and Schedule III requirements.
- The company continues its transition and reporting under the new name Cohance Lifesciences (formerly Suven Pharmaceuticals).
Cohance Lifesciences reported a weak Q3 FY26 with revenue declining 19.5% YoY to ₹5,446 mn and Adjusted PAT plunging 87.3% to ₹211 mn. The company has revised its FY26 revenue guidance from a flat outlook to an early-to-mid double-digit decline, citing inventory normalization and regulatory disruptions. Despite the downturn, gross margins improved to 72.8% for 9M FY26, and the company maintains a healthy cash position of ₹4.32 Bn. Management views FY26 as a transition year and expects a return to growth in FY27.
- 9M FY26 Adjusted EBITDA fell 43.4% YoY to ₹3,477 mn, with margins compressing from 34.8% to 21.1%.
- Pharma CDMO revenue for Q3 fell to ₹2,105 mn, impacted by customer-led inventory normalization and payload timing.
- Regulatory issues at the Nacharam plant led to a Warning Letter and approximately ₹55 crore in shipment deferrals.
- Company generated ₹1.75 Bn in free cash flow during 9M FY26 despite significant operational headwinds.
- Revised FY26 outlook projects a double-digit revenue decline, shifting the recovery timeline to FY27.
Cohance Lifesciences (formerly Suven Pharmaceuticals) reported a weak set of numbers for Q3 FY26, with consolidated revenue falling 19.5% YoY to ₹544.55 crore. Net profit saw a massive decline of 81%, dropping to ₹29.02 crore from a restated ₹153.48 crore in the previous year's corresponding quarter. The results are heavily impacted by the restatement of accounts following the merger of Casper Pharma and the erstwhile Cohance Lifesciences. Additionally, an exceptional cost of ₹4.86 crore was recorded due to new labor code implementations.
- Consolidated Revenue from operations fell to ₹544.55 crore in Q3 FY26 from ₹676.23 crore (restated) in Q3 FY25.
- Consolidated Net Profit plummeted 81% YoY to ₹29.02 crore compared to ₹153.48 crore in the year-ago period.
- Consolidated EPS for the quarter stood at ₹0.96, down significantly from ₹4.02 in Q3 FY25.
- Total expenses remained high at ₹505.25 crore despite the drop in revenue, impacting operating margins.
- Exceptional items for the quarter included a ₹4.86 crore charge for the implementation of new labor codes.
Cohance Lifesciences (formerly Suven Pharmaceuticals) has received a formal Warning Letter from the USFDA for its Finished Dosage Formulations (FDF Unit-I) facility in Nacharam, Hyderabad. This follows an August 2025 inspection that resulted in six observations and an 'Official Action Indicated' (OAI) classification. The company noted that the facility's contribution to consolidated FY25 revenue is less than 2%, with an EBITDA impact of less than 1%. Management is currently preparing a comprehensive response and implementing corrective actions to address the regulator's concerns.
- USFDA issued a Warning Letter for the FDF Unit-I facility following an inspection in August 2025.
- The facility was previously classified as Official Action Indicated (OAI) based on six observations.
- Financial impact is limited, with the unit contributing less than 2% of consolidated FY25 revenues.
- EBITDA contribution from the affected facility is less than 1% of the company's total.
- Company is proactively engaging with the USFDA to submit a response within stipulated timelines.
Cohance Lifesciences has received a formal Warning Letter from the USFDA regarding its Finished Dosage Formulations facility (FDF Unit-I) in Nacharam, Hyderabad. This follows an inspection conducted in August 2025 and a previous classification of the site as Official Action Indicated (OAI). Management has clarified that the financial impact is limited, as US revenues from this facility contributed less than 2% of consolidated revenues in FY2025. The company is currently working with the regulator to address compliance concerns and resolve the issues at the earliest.
- USFDA issued a Warning Letter for the Nacharam formulation facility following an August 2025 inspection.
- The facility's US-linked revenue accounted for less than 2% of consolidated revenues in FY2025.
- Related EBITDA contribution from the facility was less than 1% of the total in FY2025.
- The site was previously classified as Official Action Indicated (OAI) prior to this Warning Letter.
- Company is engaging with the USFDA to remediate the observations and ensure regulatory compliance.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has announced the resignation of Mr. Kundan Kumar Jha from his roles as Company Secretary, Compliance Officer, and Head-Legal. The resignation will be effective from the close of business hours on February 4, 2026. Mr. Jha submitted his resignation on November 7, 2025, to pursue external opportunities and is serving a standard notice period to ensure a smooth transition. The company will need to appoint a successor to manage its regulatory and legal compliance functions.
- Mr. Kundan Kumar Jha resigns as Company Secretary, Compliance Officer, and Head-Legal
- The resignation is effective from the close of business hours on February 4, 2026
- The formal resignation email was submitted on November 7, 2025, allowing for a nearly 3-month transition period
- Departure is cited as being for new professional opportunities outside the organization
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has announced the successful passage of a postal ballot resolution to appoint Mr. Himanshu Agarwal as a Whole-time Director. The resolution was passed with a significant majority, receiving 96.86% of the total 341,759,221 votes polled. While the promoter group voted 100% in favor, institutional investors showed a minor dissent with 11.07% of their votes cast against the appointment. The high overall turnout of 89.33% indicates strong shareholder participation in the company's governance.
- Appointment of Mr. Himanshu Agarwal as Whole-time Director approved with 96.86% majority.
- Total voter turnout was high at 89.33%, representing over 34.17 crore shares.
- Institutional investors cast 9.67 crore votes, with 88.93% in favor and 11.07% against.
- Promoter and Promoter Group (holding 21.99 crore shares) voted 100% in favor of the resolution.
- The resolution was officially passed on January 22, 2026, following a month-long e-voting period.
Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals, has scheduled a conference call for investors and analysts on February 12, 2026, at 6:15 PM IST. The call is intended to discuss the company's un-audited financial results for the third quarter and nine months ended December 31, 2025. The financial results are scheduled to be considered and approved by the board earlier on the same day. This routine interaction allows the investment community to gain insights into the company's operational performance and management's future outlook.
- Conference call scheduled for February 12, 2026, at 6:15 PM IST following the board meeting.
- The session will cover Un-audited Financial Results for Q3 and 9M FY26.
- Management discussion will be followed by an interactive Question & Answer session.
- Primary dial-in numbers for the call are +91 22 6280 1141 and +91 22 7115 8042.
- International toll-free numbers are available for Singapore, Hong Kong, USA, and UK.
Cohance Lifesciences has appointed Mr. Sunil Kumar Singh as Chief Quality Officer and Senior Management Personnel, effective January 19, 2026. Mr. Singh brings over 35 years of extensive experience in pharmaceutical quality management across APIs, formulations, and CDMO sectors. He previously served as the Global Head of Quality for the PSAI Business at Dr. Reddy’s Laboratories and held senior roles at Mylan and Cipla. This strategic hire is intended to strengthen the company's regulatory compliance and quality governance frameworks.
- Mr. Sunil Kumar Singh appointed as Chief Quality Officer and Senior Management Personnel effective January 19, 2026.
- Brings over 35 years of leadership experience in pharmaceutical quality, including APIs and CDMO ecosystems.
- Former Global Head of Quality for PSAI Business and Global Head of Internal Audit at Dr. Reddy’s Laboratories.
- Extensive career history with leading pharmaceutical firms including Mylan, Zydus, Glenmark, and Cipla.
- Focus will be on science-driven quality transformation, digitalization, and proactive risk governance.
Cohance Lifesciences Limited has approved the grant of 3,89,668 stock options to eligible employees under its Employee Stock Option Plan 2023. A significant portion of this grant, totaling 2,18,077 options, is issued in accordance with the Scheme of Amalgamation with the erstwhile Cohance Lifesciences. The remaining 1,71,591 options follow a standard vesting schedule of 1 to 10 years. Each option is convertible into one equity share of face value Re. 1 upon exercise.
- Total grant of 3,89,668 stock options approved by the Nomination and Remuneration Committee
- Includes 2,18,077 options granted to employees of the transferor company following the NCLT-approved merger
- Merger-related options are scheduled to vest on April 1, 2026, accounting for prior holding periods
- New grants of 1,71,591 options have a minimum vesting period of 1 year and a maximum of 10 years
- Exercise period is fixed at 3 years from the date of vesting for all granted options
Cohance Lifesciences Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document, provided by KFin Technologies, confirms that all share dematerialization and rematerialization requests for the quarter ended December 31, 2025, were handled correctly. This data has been reported to the BSE and NSE as per statutory requirements. This filing is a standard administrative task and does not impact the company's financial performance or strategic direction.
- Quarterly compliance certificate submitted for the period ending December 31, 2025.
- Confirmation received from Registrar and Share Transfer Agent, KFin Technologies Limited.
- Verification of dematerialized and rematerialized securities completed as per SEBI norms.
- Filing covers requirements for both BSE (Scrip Code: 543064) and NSE (Symbol: COHANCE).
Financial Performance
Revenue Growth by Segment
Pharma CDMO accounts for 62% of revenue (INR 736.9 Cr in FY25) but saw an 8% YoY decline in Q2 FY26 due to destocking; Specialty Chemicals grew 166% YoY in H1 FY26 on a low base; API+ segment declined 22% YoY in H1 FY26 due to shipment delays.
Geographic Revenue Split
85% of total revenue is derived from exports to global markets, providing a broad international footprint but high exposure to global trade dynamics.
Profitability Margins
Gross margins expanded to 73.8% in H1 FY26 from 70% YoY due to a favorable product mix; Adjusted PAT margin stood at 11.8% for H1 FY26 (INR 130.2 Cr) compared to 20.7% in the previous year.
EBITDA Margin
Adjusted EBITDA margin was 23.8% in H1 FY26 (INR 263 Cr), a decrease from 32.3% YoY, reflecting upfront investments in employee costs and transition expenses; FY25 adjusted EBITDA margin was 37%.
Capital Expenditure
INR 106 Cr (INR 1.06 billion) was deployed in H1 FY26, primarily targeted at the Nacharam facility expansion for oligo and high-containment capabilities.
Credit Rating & Borrowing
Maintains a 'Positive' outlook from CRISIL with minimal reliance on external debt; consolidated repayment obligations are less than INR 40 Cr against projected accruals of over INR 600 Cr in FY26.
Operational Drivers
Raw Materials
Not specifically disclosed; referred to generally as materials for semi-finished and finished goods inventory.
Capacity Expansion
Expanding Nacharam facility for oligo and high-containment capabilities; targeting 10 DMF filings in FY26 across US and Europe to build a new customer pipeline.
Raw Material Costs
Material costs were INR 289.3 Cr in H1 FY26, representing approximately 26.2% of revenue; material margins improved to 74.6% in Q2 FY26 due to yield improvements.
Manufacturing Efficiency
Material margin improved from 71.3% to 74.6% YoY in Q2 FY26, driven by business mix and ongoing yield efficiencies.
Strategic Growth
Expected Growth Rate
20-25%
Growth Strategy
Achieving growth through the amalgamation of Casper Pharma to double operating income; integration of high-growth platforms NJ Bio (ADCs) and Sapala Organics (Oligos); and commercializing 5 new products in FY26.
Products & Services
Pharma CDMO services, Specialty Chemicals, AgChem intermediates, APIs, Antibody Drug Conjugates (ADC), and Oligo drugs.
Brand Portfolio
Cohance Lifesciences, NJ Bio, Sapala Organics.
New Products/Services
5 new products to be commercialized in FY26; Niche technologies (ADCs/Oligos) expected to reach low 20s % of CDMO revenue by end of FY26.
Market Expansion
Targeting 10 DMF filings in US and Europe; active business development in Japan and Europe following CPHI Frankfurt 2025.
Strategic Alliances
Acquisition of majority stakes in NJ Bio Inc and Sapala Organics; merger with Casper Pharma Private Limited.
External Factors
Industry Trends
Industry shifting toward India for CDMO services; increasing demand for complex modalities like Antibody Drug Conjugates (ADCs) and Oligonucleotides.
Competitive Landscape
Facing increased competition in the merchant API segment as large integrated pharma companies divest their API businesses.
Competitive Moat
Moat built on technical depth in niche technologies (>17% of revenue) and high-containment manufacturing which are difficult to replicate.
Macro Economic Sensitivity
Highly sensitive to global pharmaceutical R&D spending and the 'China+1' sourcing strategy adopted by global innovators.
Consumer Behavior
Global innovators are increasingly seeking to diversify supply chains away from China, benefiting Indian CDMOs with strong compliance records.
Geopolitical Risks
Exposed to evolving trade policies and geopolitical uncertainties that could disrupt the global pharma supply chain.
Regulatory & Governance
Industry Regulations
Subject to stringent USFDA and global regulatory standards; currently managing an OAI status at the Nacharam formulations plant.
Taxation Policy Impact
Effective tax rate for H1 FY26 was approximately 23% (INR 38.8 Cr tax on INR 169 Cr adjusted PBT).
Legal Contingencies
Incurred INR 41.4 Cr in FY25 towards legal and merger-related costs linked to the integration of Cohance Lifesciences.
Risk Analysis
Key Uncertainties
Regulatory risks associated with plant audits (OAI impact); volatility in CDMO revenue due to client destocking cycles (14% impact in Q2).
Geographic Concentration Risk
High geographic concentration with 85% of revenue coming from export markets.
Technology Obsolescence Risk
Risk of failure in clinical trials for ADCs using the company's specific payload technology, which could impact long-term pipeline revenue.
Credit & Counterparty Risk
Low risk given the strong liquidity position with INR 391 Cr in cash and liquid investments as of June 2025.